GINKGO BIOWORKS Reports 89% YoY Revenue Increase for Q4 FY2022 with Total Revenue of -$176.5 Million

Earnings Overview

GINKGO BIOWORKS ($NYSE:DNA) reported a total revenue of USD -176.5 million as of December 31 2022, showing a year-over-year increase of 89.0%, in its earnings results for the fourth quarter of FY2022 on March 1 2023. However, its net income for the same period was USD 98.3 million, a decrease of 33.8% compared to the previous year.

Share Price

This increase was primarily driven by strong sales and strong demand for their products.

However, despite this strong financial performance, the company’s stock opened at $1.4 and closed at $1.4, down 4.8% from the previous closing price of $1.5. GINKGO BIOWORKS is a biotechnology company focused on creating and engineering organisms to solve some of the world’s biggest challenges. They are leveraging advances in biology, software, and automation to develop new products and services across a range of sectors including healthcare, nutrition, chemicals & materials, and more. Their current advanced platform consists of a full stack of technologies, from algorithms and software to hardware and wet lab systems, allowing them to design and build novel organisms faster than ever before. Overall, GINKGO BIOWORKS reported strong financial performance for Q4 FY2022 with a 89% YoY increase in revenue. With their advanced platform and expanding customer base, GINKGO BIOWORKS is well positioned to capitalize on the growing demand for their products and services in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…

Key Ratios Snapshot

Some of the financial key ratios for Ginkgo Bioworks are shown below. More…

Analysis

At GoodWhale, we analyze GINKGO BIOWORKS‘s financial and business fundamentals to help investors make informed decisions. Our Risk Rating for GINKGO BIOWORKS is a medium risk investment. This means that there are some financial and business risks associated with investing in GINKGO BIOWORKS–but nothing out of the ordinary. For more in-depth information, GoodWhale users have access to our detailed risk warnings. We have detected three risk warnings across the balance sheet, cashflow statement, and financial journal. These warnings can give insights into areas where GINKGO BIOWORKS may be vulnerable so you can make a more informed choice. Sign up now to discover the risk warnings we’ve identified. More…

Peers

The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.

– Abivax SA ($OTCPK:AAVXF)

Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.

Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.

– Atreca Inc ($NASDAQ:BCEL)

Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.

– Kiromic BioPharma Inc ($NASDAQ:KRBP)

Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.

Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.

Summary

GINKGO BIOWORKS reported its fourth quarter earnings for FY2022 on March 1 2023, revealing a year-over-year revenue increase of 89%. Despite this growth, net income decreased 33.8% from the previous year. This news caused GINKGO BIOWORKS stock to dip on the day of the announcement. Investors should evaluate the company’s financial results in the context of their industry peers before making a decision about investing in GINKGO BIOWORKS.

Additional factors to consider include their competitive advantage, management team, and risk profile. Doing due diligence and assessing the fundamentals will help investors determine if GINKGO BIOWORKS is a good fit for their portfolio.